{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:21:37Z","timestamp":1793496097714,"version":"4.5.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Parkinson\u2019s disease (PD) is an increasingly common neurodegenerative condition. The disease has a significant negative impact on quality of life, but a personalized management approach can help reduce disability. Pharmacotherapy with levodopa remains the cornerstone of treatment, and a gratifying and sustained response to this treatment is a supportive criterion that argues in favor of an underlying diagnosis of PD. Yet, in daily practice, it is not uncommon to encounter patients who appear to have true PD, but who nevertheless seem to lose the responsiveness to levodopa (secondary non-responders). Some patients may even fail to respond altogether (primary non-responders). Here, we address how two mechanisms of \u201cperipheral resistance\u201d may underlie this failing response to levodopa in persons with PD. The first explanation relates to impaired bowel motility leading to secondary bacterial overgrowth, and more specifically, to the excessive bacterial production of the enzyme tyrosine decarboxylase (TDC). This enzyme may convert levodopa to dopamine in the gut, thereby hampering entry into the circulation and, subsequently, into the brain. The second explanation relates to the systemic induction of the enzyme aromatic\n                    <jats:sc>l<\/jats:sc>\n                    -amino acid decarboxylase (AADC), leading to premature conversion of levodopa into dopamine, again limiting the bioavailability within the brain. We discuss these two mechanisms and focus on the clinical implications, potential treatments and directions for future research.\n                  <\/jats:p>","DOI":"10.1038\/s41531-022-00321-y","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T06:09:32Z","timestamp":1652249372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":118,"title":["Mechanisms of peripheral levodopa resistance in Parkinson\u2019s disease"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2965-8450","authenticated-orcid":false,"given":"Milan","family":"Beckers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6371-3337","authenticated-orcid":false,"given":"Bastiaan R.","family":"Bloem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4635-7876","authenticated-orcid":false,"given":"Marcel M.","family":"Verbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"321_CR1","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey, E. R., Sherer, T., Okun, M. S. & Bloem, B. R. The Emerging Evidence of the Parkinson Pandemic. J. Parkinson\u2019s Dis. 8, S3\u2013S8 (2018).","journal-title":"J. Parkinson\u2019s Dis."},{"key":"321_CR2","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.parkreldis.2014.06.001","volume":"20","author":"MC Hechtner","year":"2014","unstructured":"Hechtner, M. C. et al. Quality of life in Parkinson\u2019s disease patients with motor fluctuations and dyskinesias in five European countries. Parkinsonism Relat. Disord. 20, 969\u2013974 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"321_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/mds.20279","volume":"20","author":"S Chapuis","year":"2005","unstructured":"Chapuis, S., Ouchchane, L., Metz, O., Gerbaud, L. & Durif, F. Impact of the motor complications of Parkinson\u2019s disease on the quality of life. Mov. Disord. 20, 224\u2013230 (2005).","journal-title":"Mov. Disord."},{"key":"321_CR4","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem, B. R., Okun, M. S. & Klein, C. Parkinson\u2019s disease. Lancet 397, 2284\u2013303 (2021).","journal-title":"Lancet"},{"key":"321_CR5","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1021\/cn5001759","volume":"5","author":"AC Whitfield","year":"2014","unstructured":"Whitfield, A. C., Moore, B. T. & Daniels, R. N. Classics in Chemical Neuroscience: Levodopa. ACS Chem. Neurosci. 5, 1192\u20131197 (2014).","journal-title":"ACS Chem. Neurosci."},{"key":"321_CR6","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn, S. et al. Levodopa and the Progression of Parkinson\u2019s Disease. N. Engl. J. Med. 351, 2498\u20132508 (2004).","journal-title":"N. Engl. J. Med."},{"key":"321_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1056\/NEJMoa1809983","volume":"380","author":"CVM Verschuur","year":"2019","unstructured":"Verschuur, C. V. M. et al. Randomized Delayed-Start Trial of Levodopa in Parkinson\u2019s Disease. N. Engl. J. Med. 380, 315\u2013324 (2019).","journal-title":"N. Engl. J. Med."},{"key":"321_CR8","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"321_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1001\/archneur.1993.00540020018011","volume":"50","author":"AJ Hughes","year":"1993","unstructured":"Hughes, A. J., Daniel, S. E., Blankson, S. & Lees, A. J. A Clinicopathologic Study of 100 Cases of Parkinson\u2019s Disease. Arch. Neurol. (Chic.) 50, 140\u2013148 (1993).","journal-title":"Arch. Neurol. (Chic.)"},{"key":"321_CR10","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/mds.28406","volume":"36","author":"WRW Martin","year":"2021","unstructured":"Martin, W. R. W. et al. Is Levodopa Response a Valid Indicator of Parkinson\u2019s Disease? Mov. Disord. 36, 948\u2013954 (2021).","journal-title":"Mov. Disord."},{"key":"321_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3390\/nano8030178","volume":"8","author":"A Lopalco","year":"2018","unstructured":"Lopalco, A. et al. Transferrin Functionalized Liposomes Loading Dopamine HCl: Development and Permeability Studies across an In Vitro Model of Human Blood-Brain Barrier. Nanomaterials (Basel, Switz.) 8, 178 (2018).","journal-title":"Nanomaterials (Basel, Switz.)"},{"key":"321_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00415-010-5728-8","volume":"257","author":"M Contin","year":"2010","unstructured":"Contin, M. & Martinelli, P. Pharmacokinetics of levodopa. J. Neurol. 257, 253\u2013261 (2010).","journal-title":"J. Neurol."},{"key":"321_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/mds.26082","volume":"30","author":"PA LeWitt","year":"2015","unstructured":"LeWitt, P. A. Levodopa therapy for Parkinson\u2019s disease: Pharmacokinetics and pharmacodynamics. Mov. Disord. 30, 64\u201372 (2015).","journal-title":"Mov. Disord."},{"key":"321_CR14","unstructured":"Aminoff, M. J. In Basic and Clinical Pharmacology (eds Katzung, B., Masters, S. & Trevor, A.) 483\u2013488 (McGraw-Hill) (2012)."},{"key":"321_CR15","doi-asserted-by":"crossref","unstructured":"Lieberman, A. N. & Goldstein, M. in Movement Disorders (eds. Shah, N. S. & Donald, A. G.) 83\u2013102 (Springer,1986).","DOI":"10.1007\/978-1-4684-5038-5_4"},{"key":"321_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3233\/JPD-191633","volume":"9","author":"HV Gupta","year":"2019","unstructured":"Gupta, H. V., Lyons, K. E., Wachter, N. & Pahwa, R. Long Term Response to Levodopa in Parkinson\u2019s Disease. J. Parkinson\u2019s Dis. 9, 525\u2013529 (2019).","journal-title":"J. Parkinson\u2019s Dis."},{"key":"321_CR17","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1002\/mds.26712","volume":"31","author":"J Nonnekes","year":"2016","unstructured":"Nonnekes, J. et al. Unmasking levodopa resistance in Parkinson\u2019s disease. Mov. Disord. 31, 1602\u20131609 (2016).","journal-title":"Mov. Disord."},{"key":"321_CR18","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1136\/jnnp.68.4.434","volume":"68","author":"GK Wenning","year":"2000","unstructured":"Wenning, G. K. et al. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson\u2019s disease? J. Neurol. Neurosurg. Psychiatry 68, 434\u2013440 (2000).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"321_CR19","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3389\/fnagi.2017.00206","volume":"9","author":"L Wang","year":"2017","unstructured":"Wang, L. et al. Protein-Restricted Diets for Ameliorating Motor Fluctuations in Parkinson\u2019s Disease. Front. Aging Neurosci. 9, 206 (2017).","journal-title":"Front. Aging Neurosci."},{"key":"321_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/00002826-199210000-00004","volume":"15","author":"R Astarloa","year":"1992","unstructured":"Astarloa, R., Mena, M. A., S\u00e1nchez, V., de la Vega, L. & de Y\u00e9benes, J. G. Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease. Clin. Neuropharmacol. 15, 375\u2013380 (1992).","journal-title":"Clin. Neuropharmacol."},{"key":"321_CR21","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.cgh.2008.01.001","volume":"6","author":"G Boccia","year":"2008","unstructured":"Boccia, G. et al. Dyspeptic Symptoms in Children: The Result of a Constipation-Induced Cologastric Brake? Clin. Gastroenterol. Hepatol. 6, 556\u2013560 (2008).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"321_CR22","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ijpharm.2017.08.126","volume":"533","author":"E Wollmer","year":"2017","unstructured":"Wollmer, E. & Klein, S. A review of patient-specific gastrointestinal parameters as a platform for developing in vitro models for predicting the in vivo performance of oral dosage forms in patients with Parkinson\u2019s disease. Int. J. Pharma. 533, 298\u2013314 (2017).","journal-title":"Int. J. Pharma."},{"key":"321_CR23","doi-asserted-by":"publisher","first-page":"5742","DOI":"10.3748\/wjg.v22.i25.5742","volume":"22","author":"A Mukherjee","year":"2016","unstructured":"Mukherjee, A., Biswas, A. & Das, S. K. Gut dysfunction in Parkinson\u2019s disease. World J. Gastroenterol. 22, 5742\u20135752 (2016).","journal-title":"World J. Gastroenterol."},{"key":"321_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1474-4422(15)00007-1","volume":"14","author":"A Fasano","year":"2015","unstructured":"Fasano, A., Visanji, N. P., Liu, L. W. C., Lang, A. E. & Pfeiffer, R. F. Gastrointestinal dysfunction in Parkinson\u2019s disease. Lancet Neurol. 14, 625\u2013639 (2015).","journal-title":"Lancet Neurol."},{"key":"321_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/mds.25708","volume":"29","author":"S Marrinan","year":"2014","unstructured":"Marrinan, S., Emmanuel, A. V. & Burn, D. J. Delayed gastric emptying in Parkinson\u2019s disease. Mov. Disord. 29, 23\u201332 (2014).","journal-title":"Mov. Disord."},{"key":"321_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/jnnp.52.Suppl.29","volume":"52","author":"AJ Lees","year":"1989","unstructured":"Lees, A. J. The on-off phenomenon. J. Neurol. Neurosurg. Psychiatry 52, 29\u201337 (1989).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"321_CR27","doi-asserted-by":"publisher","first-page":"15014","DOI":"10.1038\/npjparkd.2015.14","volume":"1","author":"F Brugger","year":"2015","unstructured":"Brugger, F. et al. Why is there motor deterioration in Parkinson\u2019s disease during systemic infections-a hypothetical view. NPJ Parkinson\u2019s Dis. 1, 15014 (2015).","journal-title":"NPJ Parkinson\u2019s Dis."},{"key":"321_CR28","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3389\/fneur.2019.01087","volume":"10","author":"SP van Kessel","year":"2019","unstructured":"van Kessel, S. P. & El Aidy, S. Contributions of Gut Bacteria and Diet to Drug Pharmacokinetics in the Treatment of Parkinson\u2019s Disease. Front. Neurol. 10, 1087 (2019).","journal-title":"Front. Neurol."},{"key":"321_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.parkreldis.2018.04.003","volume":"54","author":"JA Vizcarra","year":"2018","unstructured":"Vizcarra, J. A., Wilson-Perez, H. E., Fasano, A. & Espay, A. J. Small intestinal bacterial overgrowth in Parkinson\u2019s disease: Tribulations of a trial. Parkinsonism Relat. Disord. 54, 110\u2013112 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"321_CR30","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/mds.25522","volume":"28","author":"A Fasano","year":"2013","unstructured":"Fasano, A. et al. The role of small intestinal bacterial overgrowth in Parkinson\u2019s disease. Mov. Disord. 28, 1241\u20131249 (2013).","journal-title":"Mov. Disord."},{"key":"321_CR31","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/mds.23566","volume":"26","author":"M Gabrielli","year":"2011","unstructured":"Gabrielli, M. et al. Prevalence of Small Intestinal Bacterial Overgrowth in Parkinson\u2019s Disease. Mov. Disord. 26, 889\u2013892 (2011).","journal-title":"Mov. Disord."},{"key":"321_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13099-021-00420-w","volume":"13","author":"X Li","year":"2021","unstructured":"Li, X., Feng, X., Jiang, Z. & Jiang, Z. Association of small intestinal bacterial overgrowth with Parkinson\u2019s disease: a systematic review and meta-analysis. Gut Pathog. 13, 25 (2021).","journal-title":"Gut Pathog."},{"key":"321_CR33","doi-asserted-by":"publisher","first-page":"105812","DOI":"10.1016\/j.ejps.2021.105812","volume":"162","author":"Z Vinarov","year":"2021","unstructured":"Vinarov, Z. et al. Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: an UNGAP review. Eur. J. Pharm. Sci. 162, 105812 (2021).","journal-title":"Eur. J. Pharm. Sci."},{"key":"321_CR34","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.parkreldis.2014.02.019","volume":"20","author":"AH Tan","year":"2014","unstructured":"Tan, A. H. et al. Small intestinal bacterial overgrowth in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 20, 535\u2013540 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"321_CR35","doi-asserted-by":"publisher","first-page":"11663","DOI":"10.3390\/ijms222111663","volume":"22","author":"A D\u0103n\u0103u","year":"2021","unstructured":"D\u0103n\u0103u, A., Dumitrescu, L., Lefter, A., Tulb\u0103, D. & Popescu, B. O. Small Intestinal Bacterial Overgrowth as Potential Therapeutic Target in Parkinson\u2019s Disease. Int. J. Mol. Sci. 22, 11663 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"321_CR36","doi-asserted-by":"publisher","first-page":"615075","DOI":"10.3389\/fcimb.2021.615075","volume":"11","author":"Y Huang","year":"2021","unstructured":"Huang, Y. et al. Review: The Role of Intestinal Dysbiosis in Parkinson\u2019s Disease. Front. Cell. Infect. Microbiol. 11, 615075 (2021).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"321_CR37","doi-asserted-by":"publisher","first-page":"619354","DOI":"10.3389\/fcimb.2021.619354","volume":"11","author":"Z Chen","year":"2021","unstructured":"Chen, Z. et al. Association of Parkinson\u2019s Disease With Microbes and Microbiological Therapy. Front. Cell. Infect. Microbiol. 11, 619354 (2021).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"321_CR38","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00115-020-01011-x","volume":"91","author":"MM Unger","year":"2020","unstructured":"Unger, M. M. et al. The role of the gut microbiome in idiopathic Parkinson\u2019s disease. Nervenarzt 91, 1085\u20131095 (2020).","journal-title":"Nervenarzt"},{"key":"321_CR39","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s10517-017-3700-7","volume":"162","author":"VA Petrov","year":"2017","unstructured":"Petrov, V. A. et al. Analysis of Gut Microbiota in Patients with Parkinson\u2019s Disease. Bull. Exp. Biol. Med. 162, 734\u2013737 (2017).","journal-title":"Bull. Exp. Biol. Med."},{"key":"321_CR40","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","volume":"167","author":"TR Sampson","year":"2016","unstructured":"Sampson, T. R. et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson\u2019s Disease. Cell 167, 1469\u20131480.e12 (2016).","journal-title":"Cell"},{"key":"321_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08294-y","volume":"10","author":"SP van Kessel","year":"2019","unstructured":"van Kessel, S. P. et al. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson\u2019s disease. Nat. Commun. 10, 310 (2019).","journal-title":"Nat. Commun."},{"key":"321_CR42","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41531-021-00260-0","volume":"7","author":"SP van Kessel","year":"2021","unstructured":"van Kessel, S. P., Auvinen, P., Scheperjans, F. & El Aidy, S. Gut bacterial tyrosine decarboxylase associates with clinical variables in a longitudinal cohort study of Parkinsons disease. NPJ Parkinson\u2019s Dis. 7, 115 (2021).","journal-title":"NPJ Parkinson\u2019s Dis."},{"key":"321_CR43","first-page":"1055","volume":"364","author":"V Maini Rekdal","year":"2019","unstructured":"Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J. & Balskus, E. P. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Sci. (Am. Assoc. Advancement Sci.) 364, 1055 (2019).","journal-title":"Sci. (Am. Assoc. Advancement Sci.)"},{"key":"321_CR44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41531-021-00172-z","volume":"7","author":"A van Rumund","year":"2021","unstructured":"van Rumund, A. et al. Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase. NPJ Parkinson\u2019s Dis. 7, 29 (2021).","journal-title":"NPJ Parkinson\u2019s Dis."},{"key":"321_CR45","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/ana.410250616","volume":"25","author":"F Boomsma","year":"1989","unstructured":"Boomsma, F., Meerwaldt, J. D., Veld, A. J. M., Hovestadt, A. & Schalekamp, M. A. D. H. Induction of aromatic-l-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism. Ann. Neurol. 25, 624\u2013628 (1989).","journal-title":"Ann. Neurol."},{"key":"321_CR46","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/BF02532418","volume":"21","author":"MD Berry","year":"1996","unstructured":"Berry, M. D., Juorio, A. V., Li, X.- & Boulton, A. A. Aromatic L-amino acid decarboxylase: A neglected and misunderstood enzyme. Neurochem. Res. 21, 1075\u20131087 (1996).","journal-title":"Neurochem. Res."},{"key":"321_CR47","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1046\/j.1471-4159.1996.66010014.x","volume":"66","author":"JW Jahng","year":"1996","unstructured":"Jahng, J. W., Wessel, T. C., Houpt, T. A., Son, J. H. & Joh, T. H. Alternate Promoters in the Rat Aromatic l\u2010Amino Acid Decarboxylase Gene for Neuronal and Nonneuronal Expression: An In Situ Hybridization Study. J. Neurochem. 66, 14\u201319 (1996).","journal-title":"J. Neurochem."},{"key":"321_CR48","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1046\/j.1471-4159.1995.64020514.x","volume":"64","author":"C Sumi\u2010Ichinose","year":"1995","unstructured":"Sumi\u2010Ichinose, C. et al. Analysis of the Alternative Promoters that Regulate Tissue\u2010Specific Expression of Human Aromatic l\u2010Amino Acid Decarboxylase. J. Neurochem. 64, 514\u2013524 (1995).","journal-title":"J. Neurochem."},{"key":"321_CR49","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/WNF.0000000000000408","volume":"43","author":"A Rojo-Sebasti\u00e1n","year":"2020","unstructured":"Rojo-Sebasti\u00e1n, A., Gonz\u00e1lez-Robles, C. & Garc\u00eda de Y\u00e9benes, J. Vitamin B6 Deficiency in Patients With Parkinson Disease Treated With Levodopa\/Carbidopa. Clin. Neuropharmacol. 43, 151\u2013157 (2020).","journal-title":"Clin. Neuropharmacol."},{"key":"321_CR50","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/mdc3.12688","volume":"6","author":"A Romagnolo","year":"2019","unstructured":"Romagnolo, A. et al. Levodopa\u2010induced neuropathy: a systematic review. Mov. Disord. Clin. Pr. 6, 96\u2013103 (2019).","journal-title":"Mov. Disord. Clin. Pr."},{"key":"321_CR51","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/0732-8893(93)90004-Q","volume":"16","author":"WW Hoover","year":"1993","unstructured":"Hoover, W. W. et al. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn. Microbiol. Infect. Dis. 16, 111\u2013118 (1993).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"321_CR52","doi-asserted-by":"publisher","unstructured":"Moura, I. B. et al. Profiling the effects of rifaximin on the healthy human colonic microbiota using a chemostat model. bioRxiv 828269. https:\/\/doi.org\/10.1101\/828269 (2019).","DOI":"10.1101\/828269"},{"key":"321_CR53","first-page":"1421","volume":"32","author":"L Laghi","year":"2018","unstructured":"Laghi, L. et al. Impact of treatments on fecal microbiota and fecal metabolome in symptomatic uncomplicated diverticular disease of the colon: a pilot study. J. Biol. Regulators Homeost. Agents 32, 1421\u20131432 (2018).","journal-title":"J. Biol. Regulators Homeost. Agents"},{"key":"321_CR54","unstructured":"U.S. Centers for Medicare & Medicaid Services. NADAC (National Average Drug Acquisition Cost). https:\/\/data.medicaid.gov\/nadac (2022). Accessed November 25, 2021."},{"key":"321_CR55","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1365-2036.1995.tb00353.x","volume":"9","author":"AF Celik","year":"1995","unstructured":"Celik, A. F., Tomlin, J. & Read, N. W. The effect of oral vancomycin on chronic idiopathic constipation. Alimentary Pharmacol. Ther. 9, 63\u201368 (1995).","journal-title":"Alimentary Pharmacol. Ther."},{"key":"321_CR56","first-page":"52A","volume":"96","author":"TJ Borody","year":"1989","unstructured":"Borody, T. J. et al. Oral Vancomycin can reverse idiopathic constipation. Gastroenterology 96, 52A (1989).","journal-title":"Gastroenterology"},{"key":"321_CR57","first-page":"245","volume":"4","author":"P Andrews","year":"1992","unstructured":"Andrews, P., Barnes, P. & Borody, T. Chronic constipation reversed by restoration of bowel flora. A case and and a hypothesis. Eur. J. Gastroenterol. Hepatol. 4, 245\u2013247 (1992).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"321_CR58","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/jac\/dkw383","volume":"72","author":"S Isaac","year":"2017","unstructured":"Isaac, S. et al. Short- and long- term effects of oral vancomycin on the human intestinal microbiota. J. Antimicrobial Chemother. 72, 128\u2013136 (2017).","journal-title":"J. Antimicrobial Chemother."},{"key":"321_CR59","unstructured":"National Health Care Institute. Medicijnkosten. https:\/\/www.medicijnkosten.nl Accessed November 25, 2021."},{"key":"321_CR60","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.diagmicrobio.2006.08.014","volume":"57","author":"C Vay","year":"2007","unstructured":"Vay, C. et al. Antimicrobial susceptibility of non-enterococcal intrinsic glycopeptide-resistant Gram-positive organisms. Diagnostic Microbiol. Infect. Dis. 57, 183\u2013188 (2007).","journal-title":"Diagnostic Microbiol. Infect. Dis."},{"key":"321_CR61","doi-asserted-by":"publisher","first-page":"629438","DOI":"10.3389\/fcimb.2021.629438","volume":"11","author":"AH Kim","year":"2021","unstructured":"Kim, A. H. et al. Assessment of Oral Vancomycin-Induced Alterations in Gut Bacterial Microbiota and Metabolome of Healthy Men. Front. Cell. Infect. Microbiol. 11, 629438 (2021).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"321_CR62","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00284-004-4431-3","volume":"50","author":"S Delgado","year":"2005","unstructured":"Delgado, S., Fl\u00f3rez, A. & Mayo, B. Antibiotic Susceptibility of Lactobacillus and Bifidobacterium Species from the Human Gastrointestinal Tract. Curr. Microbiol 50, 202\u2013207 (2005).","journal-title":"Curr. Microbiol"},{"key":"321_CR63","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1093\/jac\/dkx318","volume":"72","author":"K Cannon","year":"2017","unstructured":"Cannon, K. et al. Enteric microbiome profiles during a randomized Phase 2 clinical trial of surotomycin versus vancomycin for the treatment of Clostridium difficile infection. J. Antimicrobial Chemother. 72, 3453\u20133461 (2017).","journal-title":"J. Antimicrobial Chemother."},{"key":"321_CR64","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.jhep.2013.11.034","volume":"60","author":"A Vrieze","year":"2013","unstructured":"Vrieze, A. et al. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J. Hepatol. 60, 824\u2013831 (2013).","journal-title":"J. Hepatol."},{"key":"321_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2021.1875109","volume":"13","author":"TPM Scheithauer","year":"2021","unstructured":"Scheithauer, T. P. M. et al. Compensatory intestinal immunoglobulin response after vancomycin treatment in humans. Gut Microbes 13, 1\u201314 (2021).","journal-title":"Gut Microbes"},{"key":"321_CR66","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1086\/506349","volume":"43","author":"TJ Louie","year":"2006","unstructured":"Louie, T. J. et al. Tolevamer, a Novel Nonantibiotic Polymer, Compared with Vancomycin in the Treatment of Mild to Moderately Severe Clostridium difficile\u2013Associated Diarrhea. Clin. Infect. Dis. 43, 411\u2013420 (2006).","journal-title":"Clin. Infect. Dis."},{"key":"321_CR67","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1111\/j.1572-0241.2007.01539.x","volume":"102","author":"J Pepin","year":"2007","unstructured":"Pepin, J., Valiquette, L., Gagnon, S., Routhier, S. & Brazeau, I. Outcomes of Clostridium difficile-Associated Disease Treated With Metronidazole or Vancomycin Before and After the Emergence of NAP1027. Am. J. Gastroenterol. 102, 2781\u20132788 (2007).","journal-title":"Am. J. Gastroenterol."},{"key":"321_CR68","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1128\/AAC.01927-15","volume":"60","author":"M Falcone","year":"2016","unstructured":"Falcone, M. et al. Risk Factors and Outcomes for Bloodstream Infections Secondary to Clostridium difficile Infection. Antimicrobial Agents Chemother. 60, 252\u2013257 (2016).","journal-title":"Antimicrobial Agents Chemother."},{"key":"321_CR69","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2217\/fmb-2020-0084","volume":"15","author":"L Boyanova","year":"2020","unstructured":"Boyanova, L., Markovska, R., Hadzhiyski, P., Kandilarov, N. & Mitov, I. Rifamycin use for treatment of Helicobacter pylori infection: a review of recent data. Future Microbiol. 15, 1185\u20131196 (2020).","journal-title":"Future Microbiol."},{"key":"321_CR70","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s10620-020-06193-7","volume":"65","author":"B Guevara","year":"2020","unstructured":"Guevara, B. & Cogdill, A. G. Helicobacter pylori: a review of current diagnostic and management strategies. Digestive Dis. Sci. 65, 1917\u20131931 (2020).","journal-title":"Digestive Dis. Sci."},{"key":"321_CR71","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1002\/mds.28248","volume":"35","author":"AH Tan","year":"2020","unstructured":"Tan, A. H. et al. Helicobacter pylori Eradication in Parkinson\u2019s disease: a randomized placebo\u2010controlled trial. Mov. Disord. 35, 2250\u20132260 (2020).","journal-title":"Mov. Disord."},{"key":"321_CR72","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.clineuro.2018.09.039","volume":"175","author":"E Dardiotis","year":"2018","unstructured":"Dardiotis, E. et al. H. pylori and Parkinson\u2019s disease: Meta-analyses including clinical severity. Clin. Neurol. Neurosurg. 175, 16\u201324 (2018).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"321_CR73","doi-asserted-by":"crossref","first-page":"e772","DOI":"10.1212\/WNL.0000000000011803","volume":"96","author":"AH Tan","year":"2021","unstructured":"Tan, A. H. et al. Probiotics for Constipation in Parkinson disease: a randomized placebo-controlled study. Neurology 96, e772\u2013e782 (2021).","journal-title":"Neurology"},{"key":"321_CR74","first-page":"117","volume":"57","author":"E Cassani","year":"2011","unstructured":"Cassani, E. et al. Use of probiotics for the treatment of constipation in Parkinson\u2019s disease patients. Minerva Gastroenterologica e Dietologica 57, 117\u2013121 (2011).","journal-title":"Minerva Gastroenterologica e Dietologica"},{"key":"321_CR75","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1212\/WNL.0000000000003127","volume":"87","author":"M Barichella","year":"2016","unstructured":"Barichella, M. et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT. Neurology 87, 1274\u20131280 (2016).","journal-title":"Neurology"},{"key":"321_CR76","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00003088-200645020-00001","volume":"45","author":"D Nyholm","year":"2006","unstructured":"Nyholm, D. Pharmacokinetic Optimisation in the Treatment of Parkinsons disease: an update. Clin. Pharmacokinet. 45, 109\u2013136 (2006).","journal-title":"Clin. Pharmacokinet."},{"key":"321_CR77","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1021\/mp100036b","volume":"7","author":"L Diao","year":"2010","unstructured":"Diao, L., Shu, Y. & Polli, J. E. Uptake of pramipexole by human cation transporters. Mol. Pharma. 7, 1342\u20131347 (2010).","journal-title":"Mol. Pharma."},{"key":"321_CR78","first-page":"bcr-223722","volume":"2018","author":"T Ogawa","year":"2018","unstructured":"Ogawa, T., Oyama, G. & Hattori, N. Transdermal rotigotine patch in Parkinson\u2019s disease with a history of intestinal operation. BMJ Case Rep. 2018, bcr-223722 (2018).","journal-title":"BMJ Case Rep."},{"key":"321_CR79","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1474-4422(18)30405-8","volume":"18","author":"PA LeWitt","year":"2019","unstructured":"LeWitt, P. A. et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 18, 145\u2013154 (2019).","journal-title":"Lancet Neurol."},{"key":"321_CR80","doi-asserted-by":"publisher","first-page":"16023","DOI":"10.1038\/npjparkd.2016.23","volume":"2","author":"KR Chaudhuri","year":"2016","unstructured":"Chaudhuri, K. R. et al. Non-oral dopaminergic therapies for Parkinson\u2019s disease: current treatments and the future. NPJ Parkinson\u2019s Dis. 2, 16023 (2016).","journal-title":"NPJ Parkinson\u2019s Dis."},{"key":"321_CR81","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S1474-4422(19)30396-5","volume":"19","author":"CW Olanow","year":"2020","unstructured":"Olanow, C. W. et al. Apomorphine sublingual film for off episodes in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 19, 135\u2013144 (2020).","journal-title":"Lancet Neurol."},{"key":"321_CR82","doi-asserted-by":"crossref","unstructured":"Camacho, M., Greenland, J. C. & Williams\u2010Gray, C. H. The Gastrointestinal Dysfunction Scale for Parkinson\u2019s Disease. Mov. Disord. 36, 2358\u20132366 (2021).","DOI":"10.1002\/mds.28675"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00321-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00321-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00321-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T09:16:14Z","timestamp":1669281374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00321-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,11]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["321"],"URL":"https:\/\/doi.org\/10.1038\/s41531-022-00321-y","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,11]]},"assertion":[{"value":"23 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}